Recursion Pharmaceuticals, Inc. Class A Common Stock
RXRXStock
$3.02−36.59%52W
Market Cap$1.76B
P/E—
Div yield—
Beta1.07
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-41.35%
Price vs S&P 500 (4W)3.49%
VGM Score44.68
Market Capitalization$1.76B
Earnings Surprise History
Q1 26-0.22est. -0.28
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
3.71
3.71
3.71
3.71
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock | C | C | D | $3.02 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Recursion Pharmaceuticals is a clinical-stage biotech company that integrates computational and experimental technologies—including chemistry, automation, and data science—to accelerate drug discovery and industrialize development. The platform aims to decode biological processes and de-risk the path from research to therapeutic approval. U.S. operations represent the company's primary revenue source, with additional presence in the United Kingdom and other markets.